FDA Determines Regulatory Review Period for Tukysa Patent Extension

Summary

The U.S. Food and Drug Administration (FDA) has published a notice stating that it has determined the regulatory review period for Tukysa, a human drug product, in order to extend its patent, following submissions to the U.S. Patent and Trademark Office (USPTO).